Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23524440 | 0.98 | KMT2A (0.57) | KMT2AHTR2A | |
| SCHEMBL1240176 | 0.89 | KMT2A (0.47) | KMT2A | |
| SCHEMBL5018903 | 0.85 | GABRA1 (0.48) | — | |
| SCHEMBL393804 | 0.84 | HTR2A (0.57) | HTR2ATAAR1 | |
| SCHEMBL393805 | 0.84 | HTR2A (0.57) | HTR2ATAAR1 | |
| SCHEMBL30249073 | 0.83 | KMT2A (0.64) | KMT2AHTR2ATAAR1 | |
| SCHEMBL266563 | 0.83 | KMT2A (0.64) | KMT2AHTR2ATAAR1 | |
| SCHEMBL14655700 | 0.83 | KMT2A (0.64) | KMT2AHTR2ATAAR1 | |
| SCHEMBL268369 | 0.83 | CA12 (0.52) | TAAR1 | |
| SCHEMBL30392457 | 0.83 | CA12 (0.52) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-103140580-B | Aminotransferase, gene encoding the same, and method for using the same | KANEKA CORP. (JP) | 2016-06-01 | — | — | CN | claimed |
| CN-103534350-B | Aminotransferase exhibiting high activity for glutamic acid, gene encoding the same, and method for using the same | KANEKA CORP. (JP) | 2016-03-09 | — | — | CN | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| CN-103534350-A | Novel aminotransferase exhibiting high activity for glutamic acid, gene encoding the same, and method for using the same | KANEKA CORP | 2014-01-22 | — | — | CN | claimed |
| CN-103534353-A | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORP | 2014-01-22 | — | — | CN | claimed |
| CN-103140580-A | Novel aminotransferase, gene encoding the same, and method for using the same | KANEKA CORP | 2013-06-05 | — | — | CN | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| CN-102170874-A | Compositions and methods for treating psychiatric disorders | GOSFORTH CT HOLDINGS PTY LTD | 2011-08-31 | — | — | CN | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| US-7550375-B2 | Method for forming metal bumps | ADVANCED SEMICONDUCTOR ENGINEERING INC. (TW) | 2009-06-23 | — | — | US | claimed |
| US-20070218676-A1 | Method for forming metal bumps | ADVANCED SEMICONDUCTOR ENGINEERING INC. (TW) | 2007-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | KMT2A 1149/4885HTR2A 14/4885TAAR1 79/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | KMT2A 1312/4885HTR2A 62/4885TAAR1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.